Patent intelligence · US
US 12016853
Methods of treating RBP4 related diseases with triazolopyridines
Methods of treating RBP4 related diseases with triazolopyridines
Patent details — US 12016853
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 25, 2024
- Expiration
- Jun 20, 2044
- Applicant
- Belite Bio, Inc
- Claims
- 20
- CPC classes
- A61K, A61K31/4545, A61K31/4985, A61K31/519
Quick answer
US 12016853 (Methods of treating RBP4 related diseases with triazolopyridines) is held by Belite Bio, Inc. Status: granted. Granted Jun 25, 2024. Expires Jun 20, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Belite Bio, Inc
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/4545, A61K31/4985, A61K31/519, A61K31/5365, A61K31/5383
More from Belite Bio, Inc
Related pharmaceutical patents in our USPTO index.
-
US 12364693
Methods of treating metabolic diseases with fused bicyclic pyrazoles
granted -
US 12295394
Water-soluble additive composition
granted -
US 12116596
Method and apparatus for improved mesenchymal stem cell harvesting
granted -
US 11951100
Formulations of RBP4 inhibitors and methods of use
granted -
US 11723873
Oral dosage form of ticagrelor and preparation method thereof
granted -
US 11684596
Antidiabetic pharmaceutical compositions and preparation method thereof
granted -
US 11655454
Method and apparatus for improved mesenchymal stem cell harvesting
granted
Frequently asked questions
What is US patent 12016853?
US 12016853 (Methods of treating RBP4 related diseases with triazolopyridines) is held by Belite Bio, Inc. Status: granted. Granted Jun 25, 2024. Expires Jun 20, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12016853?
Belite Bio, Inc is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.
When does US 12016853 expire?
Our index shows an expiration date of Jun 20, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.